MedTrace Logo

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

NCT06774027 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-12-18

No results posted yet for this study

Summary

Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical trials in patients with metastatic triple negative breast cancer (mTNBC) and hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer (MBC), offering an effective new treatment strategy. Several outstanding questions drive the decision to use ADC drugs clinically. This is a prospective, multi-site observational study of patients with metastatic breast cancer (mBC) who are being treated with FDA-approved antibody drug conjugates (ADCs) as part of routine care and aims to collect real-world data to evaluate the impact of ADC treatment as part of routine care.

Conditions

Interventions

PROCEDURE

Specimen collection

Blood specimens will be collected during regular clinical visits for correlative and exploratory analysis

DRUG

Non-Investigational Antibody-Drug Conjugates (ADC)

ADC given under usual care for the treatment of cancer

OTHER

Medical Record Review

Prospective and retrospective medical chart reviews will be conducted to obtain data for analysis.

Sponsors & Collaborators

Principal Investigators

  • Laura Huppert, MD,BA · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-08
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06774027 on ClinicalTrials.gov